Previous Close | $20.30 |
Intrinsic Value | $840.87 |
Upside potential | +4,042% |
Data is not available at this time.
Castle Biosciences, Inc. operates in the diagnostics sector, specializing in genomic and molecular testing to improve patient care in dermatologic cancers and other diseases. The company generates revenue primarily through its proprietary diagnostic tests, such as DecisionDx-Melanoma and DecisionDx-SCC, which provide actionable insights for treatment planning. Castle Biosciences differentiates itself through clinically validated, high-complexity tests that address unmet medical needs, positioning it as a leader in precision diagnostics for skin cancer. The company’s focus on innovation and evidence-based solutions strengthens its competitive edge in a rapidly evolving healthcare landscape. Its tests are widely adopted by clinicians, reinforcing its market presence and supporting long-term growth in the expanding molecular diagnostics industry. By leveraging its scientific expertise and strategic collaborations, Castle Biosciences maintains a strong foothold in niche markets with high barriers to entry.
Castle Biosciences reported revenue of $332.1 million for FY 2024, reflecting its ability to scale its diagnostic offerings. The company achieved net income of $18.2 million, with diluted EPS of $0.62, demonstrating improved profitability. Operating cash flow was robust at $64.9 million, supported by efficient operations and disciplined cost management. Capital expenditures of $28.3 million indicate ongoing investments in capacity and innovation.
The company’s earnings power is underscored by its ability to convert revenue into net income, with a net margin of approximately 5.5%. Operating cash flow significantly exceeds net income, highlighting strong cash generation capabilities. Capital efficiency is evident as the company balances growth investments with profitability, maintaining a lean operational structure while expanding its test portfolio.
Castle Biosciences maintains a solid balance sheet, with $119.7 million in cash and equivalents, providing liquidity for growth initiatives. Total debt stands at $26.3 million, indicating a conservative leverage profile. The company’s financial health is further supported by positive operating cash flow, ensuring flexibility to fund R&D and commercialization efforts without over-reliance on external financing.
Revenue growth reflects increasing adoption of Castle Biosciences’ tests, driven by clinical utility and expanding indications. The company does not currently pay dividends, opting to reinvest cash flows into growth opportunities. Future trends may include geographic expansion and new product launches, supported by a strong pipeline and strategic partnerships.
The market values Castle Biosciences based on its growth potential in precision diagnostics, with investors likely pricing in future test adoption and pipeline developments. Valuation metrics should be assessed against peers in the high-growth molecular diagnostics space, where premium multiples are common due to innovation-driven upside.
Castle Biosciences benefits from proprietary technology, strong clinical validation, and a focused commercial strategy. The outlook remains positive, with opportunities to expand test utilization and enter new markets. Risks include reimbursement dynamics and competition, but the company’s differentiated offerings and execution track record position it well for sustained growth.
Company filings, investor presentations
show cash flow forecast
Fiscal year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
Revenue growth rate, % | NaN | |||||||||||||||||||||||||
Revenue, $ | NaN | |||||||||||||||||||||||||
Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
Total operating expenses, $m | NaN | |||||||||||||||||||||||||
Operating income, $m | NaN | |||||||||||||||||||||||||
EBITDA, $m | NaN | |||||||||||||||||||||||||
Interest expense (income), $m | NaN | |||||||||||||||||||||||||
Earnings before tax, $m | NaN | |||||||||||||||||||||||||
Tax expense, $m | NaN | |||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
Total assets, $m | NaN | |||||||||||||||||||||||||
Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
Average production assets, $m | NaN | |||||||||||||||||||||||||
Working capital, $m | NaN | |||||||||||||||||||||||||
Total debt, $m | NaN | |||||||||||||||||||||||||
Total liabilities, $m | NaN | |||||||||||||||||||||||||
Total equity, $m | NaN | |||||||||||||||||||||||||
Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
Net income, $m | NaN | |||||||||||||||||||||||||
Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
Funds from operations, $m | NaN | |||||||||||||||||||||||||
Change in working capital, $m | NaN | |||||||||||||||||||||||||
Cash from operations, $m | NaN | |||||||||||||||||||||||||
Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
New CAPEX, $m | NaN | |||||||||||||||||||||||||
Total CAPEX, $m | NaN | |||||||||||||||||||||||||
Free cash flow, $m | NaN | |||||||||||||||||||||||||
Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
Discount rate, % | NaN | |||||||||||||||||||||||||
PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
Current shareholders' claim on cash, % | NaN |